Testing the validity of cost-effectiveness models.
نویسندگان
چکیده
A growing body of recent work has identified several problems with economic evaluations undertaken alongside controlled trials that can have potentially serious impacts on the ability of decision makers to draw valid conclusions. At the same time, the use of cost-effectiveness models has been drawn into question, due to the alleged arbitrary nature of their construction. This has led researchers to try and identify ways of improving the quality of cost-effectiveness models through identifying 'best practice', producing guidelines for peer review and identifying tests of validity. This paper investigates the issue of testing the validity of cost-effectiveness models or, perhaps more appropriately, whether it is possible to objectively measure the quality of a cost-effectiveness model. A review of the literature shows that there is much confusion over the different aspects of modelling that should be assessed in respect to model quality, and how this should be done. We develop a framework for assessing model quality in terms of: (i) the structure of the model; (ii) the inputs of the model; (iii) the results of the model; and (iv) the value of the model to the decision maker. Quality assessment is investigated within this framework, and it is argued that it is doubtful that a set of objective tests of validity will ever be produced, or indeed that such an approach would be desirable. The lack of any clearly definable and objective tests of validity means that the other parts of the evaluation process need to be given greater emphasis. Quality assurance forms a small part of a broader process and is best implemented in the form of good practice guidelines. A set of key guidelines are presented.
منابع مشابه
Pnm-17: Cost Effectiveness of Human Papillomavirus Testing in Cervical Cancer Diagnosis
Background: Epidemiological studies are shown robust association between human papillomavirus (HPV) and cervical cancer. From 1990 HPV was known as a necessary but insufficient cause of cervical invasive cancer. The purpose of this study was to evaluate the cost effectiveness of HPV test in cervical cancer screening. Materials and Methods: This is a systematic review article; the newest scienti...
متن کاملThe clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
OBJECTIVE To determine whether testing for cytochrome P450 (CYP) polymorphisms in adults entering antipsychotic treatment for schizophrenia leads to improvement in outcomes, is useful in medical, personal or public health decision-making, and is a cost-effective use of health-care resources. DATA SOURCES The following electronic databases were searched for relevant published literature: Cochr...
متن کاملCharacterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions; Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling”
With their article, Grutters et al raise an important question: What do successful health technology assessments (HTAs) look like, and what is their real-world utility in decision-making? While many HTAs are published in peer-reviewed journals, many are considered proprietary and their attributes remain confidential, limiting researchers’ ability to answer these questio...
متن کاملApplying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran
HPV vaccine has been recently added to the Iran Drug List, so decision makers need information beyond that available from RCTs to recommend funding for this vaccination. Modeling and economic studies have addressed some of those information needs. We reviewed cost effectiveness studies to find a suitable model for Iranian population to determine the potential cost effectiveness of HPV vaccine p...
متن کاملApplying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran
HPV vaccine has been recently added to the Iran Drug List, so decision makers need information beyond that available from RCTs to recommend funding for this vaccination. Modeling and economic studies have addressed some of those information needs. We reviewed cost effectiveness studies to find a suitable model for Iranian population to determine the potential cost effectiveness of HPV vaccine p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- PharmacoEconomics
دوره 17 5 شماره
صفحات -
تاریخ انتشار 2000